13F Holdings
中文EN

ZYME Zymeworks Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1937653 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY97.8%
TTM net income YoY168.3%
TTM EPS YoY162.4%
Revenue 3-yr CAGR-16.8%
Net income 3-yr CAGR-40.5%

Margins

Gross margin—
Operating margin16.6%
Net margin16.3%
FCF margin-42.4%
EBITDA margin18.0%

Returns

ROE15.0%
ROA5.5%
ROIC (approx.)11.7%
Asset turnover0.34x

Leverage & solvency

Liabilities / assets78.0%
Debt / equity1.31x
Current ratio3.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-2.59x
Accruals ratio19.7%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$105.97M$76.30M$76.01M$412.48M$26.68M
R&D expense$137.00M$134.62M$143.62M$208.60M$199.75M
SG&A expense$61.51M$61.51M$70.45M$73.36M$42.56M
Operating income-$92.55M-$137.11M-$138.05M$130.53M-$215.63M
Pretax income-$79.75M-$116.61M-$119.24M$135.23M-$212.36M
Income tax$1.38M$6.08M-$568,000$10.89M-$516,000
Net income-$81.13M-$122.69M-$118.67M$124.34M-$211.84M
EBITDA-$88.88M-$132.92M-$130.59M$136.75M-$211.89M
EPS (basic)-1.08-1.62-1.721.91-4.11
EPS (diluted)-1.08-1.62-1.721.90-4.61
Weighted avg. shares (diluted)75.41M75.88M68.86M65.25M52.13M
Balance sheet
Cash & equivalents$41.16M$66.10M$157.56M$400.91M$201.87M
Short-term investments——$216.77M$91.32M$50.74M
Receivables$4.64M$55.81M$19.48M$33.40M$15.61M
Current assets$248.77M$300.45M$412.93M$544.71M$288.22M
PP&E, net$15.50M$17.65M$19.85M$24.71M$22.78M
Goodwill$12.02M$12.02M$12.02M$12.02M$12.02M
Intangibles$1.35M$4.58M$7.66M$8.76M$3.84M
Total assets$346.53M$463.09M$580.88M$648.73M$389.13M
Current liabilities$42.32M$88.29M$55.76M$95.62M$71.85M
Total liabilities$78.03M$124.32M$116.07M$155.77M$140.04M
Shareholders' equity$268.50M$338.77M$464.81M$492.96M$249.09M
Shares outstanding74.64M68.96M70.12M63.06M46.63M
Cash flow statement
Operating cash flow-$33.01M-$110.06M-$118.32M$144.11M-$192.45M
Capital expenditure$1.52M$1.99M$2.47M$8.15M$12.40M
Free cash flow-$34.53M-$112.05M-$120.80M$135.96M-$204.85M
Investing cash flow$26.66M$38.76M-$207.25M-$53.85M$144.60M
Financing cash flow-$18.56M-$20.44M$81.87M$108.58M$8.01M
Depreciation & amortization$3.67M$4.19M$7.46M$6.22M$3.74M
Stock-based compensation$28.03M$17.79M$8.10M$4.01M$10.76M
Share buybacks$41.70M$30.05M$0$0—

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.